ClinicalTrials.gg
CompletedNCT04929249V-INITIATEUpdated May 16, 2025Results posted

A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)

A Phase 3 interventional study of Inclisiran in Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals. Completed at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing inclisiran in Atherosclerosis — 3 open to participants now, 7 under way, 4 of them phase 3. inclisiran · Atherosclerosis.

Enrollment
7th of 16
450 · median 401
Started
2021
with 3 others
Phase 3
8 of 16
1 open now
Registered
7th of 16
by date
Lead sponsor
9 of 16
Novartis Pharmaceuticals

Among the 16 studies testing inclisiran in Atherosclerosis, this one is the 7th largest by enrollment, is one of 4 that started in 2021, is one of 8 in phase 3, and was the 7th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

3 of the 16 studies testing inclisiran in Atherosclerosis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing inclisiran in Atherosclerosis, or all of them as a file.
02

Study summary

The purpose of this study was to assess the effectiveness of an "inclisiran first" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to achieve acceptable LDL-C with maximally tolerated statin therapy alone) compared to usual care in an atherosclerotic cardiovascular disease (ASCVD) population.

Read the detailed description

The study design was a randomized, two-arm, parallel-group, open-label, multicenter, clinical trial comparing an "inclisiran first" implementation strategy to usual care (1:1 randomization) with established ASCVD and elevated LDL-C (or non-HDL-C) despite treatment with maximally tolerated statin therapy.

Eligible patients had established ASCVD and elevated LDL-C levels ≥ 70 mg/dL (or non-HDL-C ≥ 100 mg/dL) despite treatment with maximally tolerated statin therapy.

In the "inclisiran first" implementation strategy group post-randomization, addition of other non-statin LDL-C lowering therapies (e.g., ezetimibe or bempedoic acid, excluding PCSK9 inhibiting monoclonal antibodies) were allowed to reach acceptable LDL-C levels. In the "inclisiran first" implementation strategy group, inclisiran was administered initially at randomization, 90 days later, and six months, thereafter.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease

Keywords

  • Hyperlipidemia
  • Secondary Cardiovascular Prevention
  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Hypercholesterolemia
  • Lipid lowering therapies
  • Inclisiran
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants eligible for inclusion in this study must meet all of the following criteria:

  1. Signed must be obtained prior to participation in the study
  2. Males and females ≥18 years of age
  3. History of ASCVD, documented by hospital records, claims data and/or prior laboratory/imaging assessments a Coronary heart disease (CHD):

    • Prior myocardial infarction
    • Prior coronary revascularization (PCI or CABG)
    • Angiographic or CT-imaging (e.g., MDCT/CTA) evidence of coronary atherosclerosis (>70% stenosis in at least one major epicardial coronary artery) b Cerebrovascular disease:
    • Prior ischemic stroke confirmed by a brain imaging study, CT or MRI; thought not to be caused by atrial fibrillation, valvular heart disease or mural thrombus
    • Carotid artery stenosis >70% on prior angiography or ultrasound
    • History of prior percutaneous or surgical carotid artery revascularization c Peripheral arterial disease (PAD):
    • Prior documentation of a resting ankle-brachial index ≤0.85
    • History of prior percutaneous or surgical revascularization of an iliac, femoral, or popliteal artery or aortic aneurysm
    • Prior non-traumatic amputation of a lower extremity due to peripheral artery disease
  4. Serum LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL
  5. Fasting triglyceride \<5.65 mmol/L (\<500 mg/dL) at screening
  6. Calculated >30 mL/min by estimated glomerular filtration rate (eGFR) using standardized local clinical methodology
  7. Participants should be on maximally tolerated statin therapy, as determined by the investigator, with no immediate plans to modify lipid lowering therapies. Statin intolerant patients are eligible if they had documented side effects on at least 2 different statins, including one at the lowest standard dose
  8. Participants must be willing and able to give informed consent before initiation of any study related procedures and willing to comply with all required study procedures

Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for inclusion in this study.

  1. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the participant at significant risk (according to investigator's [or delegate] judgment) if he/she participates in the clinical study
  2. An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results
  3. (NYHA) class III or IV heart failure or last known \<30%
  4. Significant cardiac arrhythmia within 3 months prior to randomization that is not controlled by medication or via ablation at the time of screening
  5. Major adverse cardiovascular event within 6 months prior to randomization
  6. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization despite antihypertensive therapy
  7. Severe concomitant non-cardiovascular disease that carries the risk of reducing to less than 2 years
  8. History of that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the two years prior to randomization
  9. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of during dosing of drug. Basic contraception methods include:

    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    3. Male sterilization (at least 6 m prior to screening). For female participants in the study, the vasectomized male partner should be the sole partner for that participant
    4. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps)
    5. Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking investigational drug.

    Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

  10. Known history of alcohol and/or drug abuse within the last 5 years (occasional casual users of illicit drugs in the opinion of the investigators are not excluded)
  11. Treatment with other investigational products or devices within 30 days or five half-lives of the screening visit, whichever is longer
  12. History of to any of the study treatments or its or to drugs of similar chemical classes
  13. Planned use of other investigational products or devices during the course of the study
  14. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:

    1. Participants who are unable to communicate or to cooperate with the investigator
    2. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including participants whose cooperation is doubtful due to drug abuse or alcohol dependency)
    3. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study - including potential participants who indicate that their participation is contingent on receiving inclisiran)
    4. Have any medical or surgical condition, which in the opinion of the investigator would put the participant at increased risk from participating in the study
    5. Persons directly involved in the conduct of the study
  15. Previous or current treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9 or ezetimibe
  16. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or (ALT) elevation >3x , aspartate aminotransferase (AST) elevation >3x ULN, or total elevation >2x ULN (except patients with Gilbert's syndrome) at screening confirmed by a repeat measurement at least one week apart
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    Inclisiran First

    Inclisiran sodium 300 mg 1.5 ml (equivalent to 284 mg of inclisiran) + usual care

    Drug: Inclisiran

  • No intervention
    Usual Care

    Treating physicians were recommended to treat patients in accordance with the 2018 ACC/AHA guidelines

Interventions

  • Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).

    Also known as: Inclisiran First

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C

    Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care at Day 330.

    Time frame: Baseline, Day 330

  2. Percentage of Participants Who Discontinued Statin Therapy

    Percentage of patients who discontinued statin therapy ≥ 30 days before the end-of-study visit of an "inclisiran first" implementation strategy compared to usual care, for patients in the FAS excluding those with a medical history of statin intolerance.

    Time frame: Day 330

Secondary outcomes

  1. Absolute Change From Baseline in LDL-C

    Absolute change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care at Day 330

    Time frame: Baseline, Day 330

  2. Average Percent Change From Baseline in LDL-C Levels Across Visits

    Average percent change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care across visits. Calculated by averaging the observed post-baseline values (percent change) for each participant across analysis visits.

    Time frame: Up to 330 Days

  3. Average Absolute Change From Baseline in LDL-C Levels Across Visits

    Average absolute change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care across visits. Calculated by averaging the observed post-baseline values (absolute change) for each participant across analysis visits.

    Time frame: Up to 330 days

  4. Percentage of Participants Achieving ≥ 50% Reduction From Baseline in LDL-C

    Percentage of patients achieving a ≥ 50% reduction from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) levels of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.

    Time frame: Baseline, Day 330

  5. Percentage of Participants Achieving LDL-C < 100 mg/dL.

    Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 100 mg/dL (among the subset of participants with LDL-C \>=100 mg/dL at baseline) of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.

    Time frame: Day 330

  6. Percentage of Participants Achieving LDL-C < 70 mg/dL

    Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 70 mg/dL of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.

    Time frame: Day 330

  7. Percentage of Participants Achieving LDL-C < 55 mg/dL

    Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 55 mg/dL of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.

    Time frame: Day 330

  8. Percent Change in Lipids and Other Lipoproteins From Baseline

    Percent change in plasma lipids, lipoproteins and triglycerides in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330

    Time frame: Baseline, Day 330

  9. Absolute Change in Lipids and Other Lipoproteins From Baseline

    Absolute change in plasma lipids, lipoproteins and triglycerides in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330

    Time frame: Baseline, Day 330

  10. Percentage of Participants by Intensity of Lipid Lowering Therapy

    Percentage of participants with decrease in dose, no change in dose or increase in dose to assess changes in background lipid-lowering therapy in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330

    Time frame: Baseline, Day 330

  11. Proportion of Days Covered by Medication

    Proportion of days covered refers to the total number of days on either statin, ezetimibe, bempedoic acid or PCSK9 inhibiting monoclonal antibody therapies taken during the study divided by total number of study days, calculated for each participant; If a participant did not take any of the four medications then the total number of days will be assumed to be zero.

    Time frame: Up to 330 Days

  12. LDL-C Measures of Variability - Standard Deviation

    Visit-to-visit LDL-C variability from Day 90 until Day 330 of an "inclisiran first" implementation strategy compared to usual care. It was assessed using two measures of variability: standard deviation and coefficient of variation.

    Time frame: Day 90, Day 180, Day 270 and Day 330

  13. LDL-C Measures of Variability - Coefficient of Variation

    Visit-to-visit LDL-C variability from Day 90 until Day 330 of an "inclisiran first" implementation strategy compared to usual care. It was assessed using two measures of variability: standard deviation and coefficient of variation.

    Time frame: Day 90, Day 180, Day 270 and Day 330

07

Results

Posted Sep 19, 2024

Participant flow

The study was conducted in 43 centers in the United States

Participant flow — Overall Study
MilestoneInclisiran FirstUsual Care
Started225225
Full analysis set (fas)225225
Safety set234216
Completed212195
Not completed1330
Withdrew: Adverse event21
Withdrew: Death21
Withdrew: Lost to follow-up311
Withdrew: Technical problems01
Withdrew: Subject decision68
Withdrew: Withdrew consent08

Outcome measures

PrimaryPercent Change From Baseline in LDL-C

Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care at Day 330.

Time frame:
Baseline, Day 330
Reported as:
Least squares mean · percent change in LDL-C
Percent Change From Baseline in LDL-C
percent change in LDL-CInclisiran FirstUsual Care
Percent Change From Baseline in LDL-C-60.0 (-64.7 to -55.2)-7.0 (-12.0 to -1.9)
Statistical analysis
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -53.0 · 97.5% CI -60.0 to -46.0
PrimaryPercentage of Participants Who Discontinued Statin Therapy

Percentage of patients who discontinued statin therapy ≥ 30 days before the end-of-study visit of an "inclisiran first" implementation strategy compared to usual care, for patients in the FAS excluding those with a medical history of statin intolerance.

Time frame:
Day 330
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Statin Therapy
Percentage of participantsInclisiran FirstUsual Care
Percentage of Participants Who Discontinued Statin Therapy6.0 (1.9 to 10.2)16.7 (10.2 to 23.1)
Statistical analysis
  • Inclisiran First vs Usual Care · Normal approx. to binomial distribution · Difference in percentage: -10.6 · 97.5% CI -18.3 to -3.0
SecondaryAbsolute Change From Baseline in LDL-C

Absolute change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care at Day 330

Time frame:
Baseline, Day 330
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in LDL-C
mg/dLInclisiran FirstUsual Care
Absolute Change From Baseline in LDL-C-58.0 (-61.6 to -54.4)-10.5 (-14.3 to -6.6)
Statistical analysis
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -47.6 · 95% CI -52.8 to -42.3
SecondaryAverage Percent Change From Baseline in LDL-C Levels Across Visits

Average percent change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care across visits. Calculated by averaging the observed post-baseline values (percent change) for each participant across analysis visits.

Time frame:
Up to 330 Days
Reported as:
Least squares mean · Average percent change in LDL-C
Average Percent Change From Baseline in LDL-C Levels Across Visits
Average percent change in LDL-CInclisiran FirstUsual Care
Average Percent Change From Baseline in LDL-C Levels Across Visits-57.2 (-60.3 to -54.0)-2.8 (-6.0 to 0.5)
Statistical analysis
  • Inclisiran First vs Usual Care · Regression, Linear · p = <0.001 · Ls mean difference: -54.4 · 95% CI -59.0 to -49.8
SecondaryAverage Absolute Change From Baseline in LDL-C Levels Across Visits

Average absolute change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care across visits. Calculated by averaging the observed post-baseline values (absolute change) for each participant across analysis visits.

Time frame:
Up to 330 days
Reported as:
Least squares mean · mg/dL
Average Absolute Change From Baseline in LDL-C Levels Across Visits
mg/dLInclisiran FirstUsual Care
Average Absolute Change From Baseline in LDL-C Levels Across Visits-55.0 (-57.8 to -52.2)-6.0 (-8.9 to -3.2)
Statistical analysis
  • Inclisiran First vs Usual Care · Regression, Linear · p = <0.001 · Ls mean difference: -48.9 · 95% CI -52.9 to -44.9
SecondaryPercentage of Participants Achieving ≥ 50% Reduction From Baseline in LDL-C

Percentage of patients achieving a ≥ 50% reduction from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) levels of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.

Time frame:
Baseline, Day 330
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ≥ 50% Reduction From Baseline in LDL-C
Percentage of participantsInclisiran FirstUsual Care
Percentage of Participants Achieving ≥ 50% Reduction From Baseline in LDL-C69.85.3
Statistical analysis
  • Inclisiran First vs Usual Care · Regression, Logistic · p = <0.001 · Odds ratio (or): 42.32 · 95% CI 22.07 to 81.16
SecondaryPercentage of Participants Achieving LDL-C < 100 mg/dL.

Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 100 mg/dL (among the subset of participants with LDL-C \>=100 mg/dL at baseline) of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.

Time frame:
Day 330
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving LDL-C < 100 mg/dL.
Percentage of participantsInclisiran FirstUsual Care
Percentage of Participants Achieving LDL-C < 100 mg/dL.80.532.1
Statistical analysis
  • Inclisiran First vs Usual Care · Regression, Logistic · p = <0.001 · Odds ratio (or): 17.32 · 95% CI 6.72 to 44.66
SecondaryPercentage of Participants Achieving LDL-C < 70 mg/dL

Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 70 mg/dL of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.

Time frame:
Day 330
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving LDL-C < 70 mg/dL
Percentage of participantsInclisiran FirstUsual Care
Percentage of Participants Achieving LDL-C < 70 mg/dL81.822.2
Statistical analysis
  • Inclisiran First vs Usual Care · Regression, Logistic · p = <0.001 · Odds ratio (or): 24.46 · 95% CI 14.18 to 42.19
SecondaryPercentage of Participants Achieving LDL-C < 55 mg/dL

Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 55 mg/dL of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.

Time frame:
Day 330
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving LDL-C < 55 mg/dL
Percentage of participantsInclisiran FirstUsual Care
Percentage of Participants Achieving LDL-C < 55 mg/dL71.68.9
Statistical analysis
  • Inclisiran First vs Usual Care · Regression, Logistic · p = <0.001 · Odds ratio (or): 35.12 · 95% CI 19.51 to 63.24
SecondaryPercent Change in Lipids and Other Lipoproteins From Baseline

Percent change in plasma lipids, lipoproteins and triglycerides in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330

Time frame:
Baseline, Day 330
Reported as:
Least squares mean · Percent change
Percent Change in Lipids and Other Lipoproteins From Baseline
Percent changeInclisiran FirstUsual Care
Total Cholesterol-34.1 (-36.7 to -31.6)-4.1 (-6.8 to -1.4)
HDL Cholesterol8.5 (6.5 to 10.6)2.0 (-0.2 to 4.2)
Non-HDL Cholesterol-49.3 (-52.7 to -46.0)-5.1 (-8.7 to -1.6)
VLDL Cholesterol-10.1 (-14.8 to -5.4)6.8 (1.8 to 11.9)
Triglycerides-10.6 (-15.3 to -5.9)7.2 (2.1 to 12.2)
Apolipoprotein B-46.4 (-49.7 to -43.1)-3.8 (-7.3 to -0.3)
Lipoprotein(a)-19.6 (-22.2 to -16.9)2.3 (-0.5 to 5.2)
Statistical analysis
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -30.1 · 95% CI -33.8 to -26.3
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: 6.6 · 95% CI 3.6 to 9.5
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -44.2 · 95% CI -49.1 to -39.3
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -16.9 · 95% CI -23.8 to -10.0
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -17.8 · 95% CI -24.7 to -10.9
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -42.6 · 95% CI -47.5 to -37.8
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -21.9 · 95% CI -25.8 to -18.0
SecondaryAbsolute Change in Lipids and Other Lipoproteins From Baseline

Absolute change in plasma lipids, lipoproteins and triglycerides in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330

Time frame:
Baseline, Day 330
Reported as:
Least squares mean · mg/dL
Absolute Change in Lipids and Other Lipoproteins From Baseline
mg/dLInclisiran FirstUsual Care
Total Cholesterol-59.6 (-63.8 to -55.5)-9.7 (-14.1 to -5.2)
HDL Cholesterol3.5 (2.6 to 4.4)0.3 (-0.6 to 1.3)
Non-HDL Cholesterol-63.0 (-66.9 to -59.1)-10.5 (-14.7 to -6.4)
VLDL Cholesterol-4.6 (-5.9 to -3.4)0.0 (-1.4 to 1.3)
Triglycerides-25.4 (-31.9 to -18.9)-0.1 (-7.0 to 6.8)
Apolipoprotein B-43.6 (-45.9 to -41.3)-7.3 (-9.8 to -4.8)
Lipoprotein(a)-9.8 (-11.1 to -8.4)-1.0 (-2.5 to 0.4)
Statistical analysis
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -49.9 · 95% CI -56.0 to -43.9
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: 3.1 · 95% CI 1.8 to 4.4
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -52.4 · 95% CI -58.1 to -46.7
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -4.6 · 95% CI -6.5 to -2.8
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -25.3 · 95% CI -34.8 to -15.8
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -36.3 · 95% CI -39.7 to -32.9
  • Inclisiran First vs Usual Care · Mixed Models Analysis · p = <0.001 · Ls mean difference: -8.7 · 95% CI -10.7 to -6.8
SecondaryPercentage of Participants by Intensity of Lipid Lowering Therapy

Percentage of participants with decrease in dose, no change in dose or increase in dose to assess changes in background lipid-lowering therapy in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330

Time frame:
Baseline, Day 330
Reported as:
Number · Percentage of participants
Percentage of Participants by Intensity of Lipid Lowering Therapy
Percentage of participantsInclisiran FirstUsual Care
Decrease in statin intensity2.34.5
No change in statin intensity97.293.0
Increase in statin intensity0.52.5
Statistical analysis
  • Inclisiran First vs Usual Care · proportional odds model · p = 0.899 · Odds ratio (or): 1.06 · 95% CI 0.43 to 2.61
SecondaryProportion of Days Covered by Medication

Proportion of days covered refers to the total number of days on either statin, ezetimibe, bempedoic acid or PCSK9 inhibiting monoclonal antibody therapies taken during the study divided by total number of study days, calculated for each participant; If a participant did not take any of the four medications then the total number of days will be assumed to be zero.

Time frame:
Up to 330 Days
Reported as:
Least squares mean · proportion of days covered
Proportion of Days Covered by Medication
proportion of days coveredInclisiran FirstUsual Care
Proportion of Days Covered by Medication0.894 ± 0.01690.902 ± 0.0169
Statistical analysis
  • Inclisiran First vs Usual Care · Regression, Linear · p = 0.727 · Ls mean difference: -0.008 · 95% CI -0.055 to 0.039
SecondaryLDL-C Measures of Variability - Standard Deviation

Visit-to-visit LDL-C variability from Day 90 until Day 330 of an "inclisiran first" implementation strategy compared to usual care. It was assessed using two measures of variability: standard deviation and coefficient of variation.

Time frame:
Day 90, Day 180, Day 270 and Day 330
Reported as:
Mean · mg/dL
LDL-C Measures of Variability - Standard Deviation
mg/dLInclisiran FirstUsual Care
Day 9042.6 ± 27.2194.3 ± 38.33
Day 18041.1 ± 28.3991.2 ± 31.61
Day 27046.2 ± 31.2288.4 ± 32.16
Day 33038.8 ± 25.3386.8 ± 35.47
SecondaryLDL-C Measures of Variability - Coefficient of Variation

Visit-to-visit LDL-C variability from Day 90 until Day 330 of an "inclisiran first" implementation strategy compared to usual care. It was assessed using two measures of variability: standard deviation and coefficient of variation.

Time frame:
Day 90, Day 180, Day 270 and Day 330
Reported as:
Number · Coefficient of Variation
LDL-C Measures of Variability - Coefficient of Variation
Coefficient of VariationInclisiran FirstUsual Care
Day 9063.9040.65
Day 18069.0034.67
Day 27067.5636.38
Day 33065.3440.89

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 330 days or until resolution.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inclisiran First2/234 (0.9%)27/234 (11.5%)64/234 (27.4%)
Usual Care1/216 (0.5%)29/216 (13.4%)53/216 (24.5%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventInclisiran FirstUsual Care
Acute myocardial infarctionCardiac disorders4/2342/216
Non-cardiac chest painGeneral disorders1/2343/216
Carotid artery stenosisNervous system disorders0/2343/216
PneumoniaInfections and infestations3/2342/216
SepsisInfections and infestations3/2341/216
FallInjury, poisoning and procedural complications3/2341/216
Coronary artery diseaseCardiac disorders1/2342/216
Urinary tract infectionInfections and infestations1/2342/216
Cerebrovascular accidentNervous system disorders1/2342/216
Transient ischaemic attackNervous system disorders1/2342/216
Most frequent other events
Most frequent other events
EventInclisiran FirstUsual Care
Injection site painGeneral disorders18/2340/216
COVID-19Infections and infestations18/23414/216
Blood creatine phosphokinase increasedInvestigations10/23413/216
Type 2 diabetes mellitusMetabolism and nutrition disorders8/23410/216
FallInjury, poisoning and procedural complications3/2349/216
Glycosylated haemoglobin increasedInvestigations9/2345/216
Urinary tract infectionInfections and infestations8/2347/216

Baseline characteristics

Age, Continuous
Age, Continuous(years)Inclisiran FirstUsual CareTotal
Mean66.3 ± 9.0166.8 ± 9.8466.5 ± 9.43
Sex: Female, Male
Sex: Female, Male(Participants)Inclisiran FirstUsual CareTotal
Female6772139
Male158153311
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Inclisiran FirstUsual CareTotal
White186187373
Black or African American272956
Asian8412
Unknown448
Multiple011
08

Study locations

43 sites
  • ARcare Center for Clinical Research .
    Little Rock, Arkansas 72205, United States
  • ARcare Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Keck Medical Center USC .
    Los Angeles, California 90033, United States
  • d-b-a Greenwich Cardio Assoc CLCZ696BUS08
    Greenwich, Connecticut 06830, United States
  • Cardiology Ass of Fairfield County .
    Stamford, Connecticut 06905, United States
  • Integrative Research Associates Inc
    Fort Lauderdale, Florida 33312, United States
  • Elite Cardiac Research Center .
    Hialeah, Florida 33012, United States
  • University of Florida Health Science Center .
    Jacksonville, Florida 32209, United States
  • Jacksonville Ctr for Clin Rea Encore Research Group
    Jacksonville, Florida 32216, United States
  • Internal Medicine and Cardiology
    Kissimmee, Florida 34741, United States
  • Gateway Cardiology PC CACZ885M2301_Younis
    Jerseyville, Illinois 62052, United States
  • Affinity Health Corp
    Oak Brook, Illinois 60523, United States
  • Northwestern Medicine Northwestern University .
    Winfield, Illinois 60190, United States
  • Indiana University Health
    Indianapolis, Indiana 46202, United States
  • St Elizabeth Healthcare .
    Edgewood, Kentucky 41017, United States
  • Alexandria Cardiology Clinic .
    Alexandria, Louisiana 71301, United States
  • Medstar Health Research Institute .
    Baltimore, Maryland 21218, United States
  • MedStar Good Samaritan Hospital
    Baltimore, Maryland 21239, United States
  • Bryan LGH Heart Inst Intigrated Cardiology Group .
    Lincoln, Nebraska 68506, United States
  • Inspira Health Network The Heart House
    Elmer, New Jersey 08318, United States
  • New Jersey Heart
    Linden, New Jersey 07036, United States
  • Montefiore Hospital .
    Bronx, New York 10467 2490, United States
  • New York Presbyterian Queens .
    Flushing, New York 11355, United States
  • New York Presbyterian Hospital .
    New York, New York 10021, United States
  • State Uni of NY at Stony Brook .
    Stony Brook, New York 11794-3362, United States
  • Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Capital Area Research LLC Suite 330
    Newport, Pennsylvania 17074, United States
  • Capital Area Research
    Newport, Pennsylvania 17074, United States
  • Cardiology Consultants of Philadelphia
    Yardley, Pennsylvania 19067, United States
  • Alliance for Multispecialty Res LLC
    Nashville, Tennessee 37203, United States
  • Cypress Heart and Vascular Center
    Cypress, Texas 77429, United States
  • NW Houston Neuro Comp Sleep Med Ctr
    Cypress, Texas 77429, United States
  • Primecare Medical Group
    Houston, Texas 77024, United States
  • Synergy Group Medical LLC .
    Houston, Texas 77061, United States
  • Synergy Group Medical LLC
    Houston, Texas 77061, United States
  • Northwest Houston Cardiology PA .
    Houston, Texas 77070, United States
  • Synergy Groups Medical LLC
    Missouri City, Texas 77459, United States
  • Bay Area Heart Ace Clinical Resh Gp .
    Webster, Texas 77598, United States
  • Centra Health .
    Lynchburg, Virginia 24501, United States
  • National Clinical Research .
    Richmond, Virginia 23294, United States
  • Exemplar Research Inc .
    Morgantown, West Virginia 26501, United States
  • Marshfield Medical Clinic .
    Marshfield, Wisconsin 54449, United States
  • Marshfield Clinic Health System
    Weston, Wisconsin 54476, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Sep 2023, 26 months.

Results were first posted in Sep 2024, 1 year after primary completion.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 26 months is below that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jun 18, 2021
StartActual
Jun 25, 2021
Primary completionActual
Sep 15, 2023
CompletionActual
Sep 15, 2023
Results first posted
Sep 19, 2024
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04929249
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Jun 25, 2021
Primary completion
Sep 15, 2023
Completion
Sep 15, 2023
Results posted
Sep 19, 2024
Last update
May 16, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion